The Breast Cancer Research Foundation (BCRF) has awarded a 1-year, $175,000 research grant to Yale Cancer Center to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.
- March 09, 2020
Invicro Collaborates with Yale’s Dr. David Rimm to Expand the Utility of Quanticell™ for Clinical Pathology ApplicationsSource: BusinessWire
BOSTON--(BUSINESS WIRE)--Invicro LLC, a Konica Minolta Company announced it has entered into a strategic research partnership with industry leading pathologist, Dr. David Rimm, MD, PhD, at The Yale University School of Medicine to advance the development of Quanticell, Konica Minolta’s proprietary tissue biomarker detection technology.
- February 05, 2020
On January 17th 2020 the National and Kapodistrian University of Athens conferred a Doctor Honoris Causa (Honorary Doctorate in Medicine) to Dr. David Rimm from Yale University.
- January 02, 2020Source: Targeted Oncology
Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer
- October 01, 2019
An all-day symposium will present the latest advances in Immuno-oncology.
- June 18, 2019
Publication in the Journal Clinical Cancer Research Uses NanoString's GeoMx Digital Spatial Profiler to Discover Predictive Biomarkers for ImmunotherapySource: Fibre2Fashion
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a publication in the journal Clinical Cancer Research of a collaborative research study led by investigators from the Yale School of Medicine. This paper represents the fourth peer-reviewed publication to describe GeoMx DSP. The article, entitled “High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling,” used the GeoMx™ Digital Spatial Profiler (DSP) to identify biomarkers that were predictive for response to immunotherapy for the treatment of melanoma.
- December 21, 2017Source: Medicine@Yale
The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.
- December 07, 2017
Yale Cancer Center (YCC) researchers attended the 40th annual San Antonio Breast Cancer Symposium (SABCS), from December 5-9, and bringing news of major advances against a disease that strikes more than 250,000 women and men in the United States each year. The Symposium is a five-day program attended by an international audience of academic and private researchers and physicians from over 90 countries.
- November 21, 2016
In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals. The finding may lead to the development of treatment based on the genetic profiles of arthritis patients, the researchers said.
- October 19, 2016Source: OncLive
David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer. Genomics testing involves an examination of the mutational or neoantigen load, explains Rimm. While this assay does select patients with a high mutational load, Rimm feels that this method is insufficiently sensitive, such that it misses those patients who may not have a high mutational load, but would still benefit from therapy. Rimm is more optimistic about another form of biomarker testing, which involves looking at the immune cell microenvironment. In this method, one can measure the distribution and properties of T-cells determined by coexpression of other markers.